Corcept Therapeutics (CORT): next trial readout expected around 2026-10-30
Trials that could report in the next 12 months: 1BiopharmaCTG
Catalyst timeline
Dates are estimated from each trial's registered completion date — none are FDA decision dates. Counts trials that fit our shared poll budget, not everything CORT is running — see methodology.
- 2026-10-30in 10wEvaluating the Pharmacokinetics and Safety of Miricorilant
Pipeline
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| Evaluating the Pharmacokinetics and Safety of Miricorilant | Phase 1 | Recruitingstill enrolling patients | 2026-10-30 | NCT07553663 |
| Extension Study to Evaluate the Safety of Long-Term Use of Relacorilan… | Phase 2 | Active Not Recruitingenrolled, still running | NCT03604198 | |
| A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonal… | Phase 2 | Active Not Recruitingenrolled, still running | NCT06108219 | |
| Dazucorilant in Patients With Amyotrophic Lateral Sclerosis | Phase 2 | Recruitingstill enrolling patients | NCT05407324 | |
| Two Part Study of Nenocorilant Combined With Nivolumab in Patients Wit… | Phase 1 | Recruitingstill enrolling patients | NCT07276373 | |
| Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Meta… | Phase 2 | Recruitingstill enrolling patients | NCT07259317 |
Status-change history
Every ClinicalTrials.gov change recorded for CORT's trials — a running history no other tracker shows.
No status changes detected yet for this ticker.
Frequently asked
When is CORT's next PDUFA date?
No disclosed PDUFA date is currently tracked for this ticker.
What phase is CORT's lead program in?
Phase 2 — active not recruiting.
Where does this data come from?
ClinicalTrials.gov v2 API (trial status + diffs) and company 8-K/press-release disclosures (PDUFA dates). Every number links to its source.